Ondansetron-induced headache Our experience in gynecological cancer

M. Veneziano, M. Framarino dei Malatesta, A. F. Bandiera, C. Fiorelli, M. Galati, A. Paolucci

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Chemotherapy-induced emesis is one of the major problems in the treatment of oncologic patients. Recently, a novel class of compounds, the selective 5HT3 receptor antagonists, has been introduced, achieving a dramatic improvement in the control of emesis. The absence of extrapyramidal side effects adds to their safety and good tolerability. The Authors herein analyse their experience on 269 cycles of chemotherapy in 47 patients treated for gynaecological and breast malignancies, with particular regard to adverse events such as headache. Their most frequent side-effects are headache and constipation, that are usually mild and self-limiting. Nevertheless, in some cases, severe, rebel headache has been reported, leading in our experience in 6.4% of cases to discontinuation of the antiemetic regimen. A previous history of recurrent or severe headache or migraine is not correlated with the occurrence of ondansetron-induced headache, as severe headache occurred after ondansetron only in 28.4% of the patients with positive anamnesis, and 70% of the patients that experienced had never suffered from severe headache before. In those patients complaining of severe headache, the Authors suggest an antiemetic association, with a loading dose of ondansetron i.v., followed by metoclopramide i.m. orally for the following days.

Original languageEnglish
Pages (from-to)203-207
Number of pages5
JournalEuropean Journal of Gynaecological Oncology
Volume16
Issue number3
Publication statusPublished - 1995

Fingerprint

Ondansetron
Headache
Neoplasms
Antiemetics
Vomiting
Drug Therapy
Metoclopramide
Constipation
Migraine Disorders
Breast
Safety

Keywords

  • Headache
  • Ondansetron
  • Side effects

ASJC Scopus subject areas

  • Obstetrics and Gynaecology
  • Oncology

Cite this

Veneziano, M., Framarino dei Malatesta, M., Bandiera, A. F., Fiorelli, C., Galati, M., & Paolucci, A. (1995). Ondansetron-induced headache Our experience in gynecological cancer. European Journal of Gynaecological Oncology, 16(3), 203-207.

Ondansetron-induced headache Our experience in gynecological cancer. / Veneziano, M.; Framarino dei Malatesta, M.; Bandiera, A. F.; Fiorelli, C.; Galati, M.; Paolucci, A.

In: European Journal of Gynaecological Oncology, Vol. 16, No. 3, 1995, p. 203-207.

Research output: Contribution to journalArticle

Veneziano, M, Framarino dei Malatesta, M, Bandiera, AF, Fiorelli, C, Galati, M & Paolucci, A 1995, 'Ondansetron-induced headache Our experience in gynecological cancer', European Journal of Gynaecological Oncology, vol. 16, no. 3, pp. 203-207.
Veneziano M, Framarino dei Malatesta M, Bandiera AF, Fiorelli C, Galati M, Paolucci A. Ondansetron-induced headache Our experience in gynecological cancer. European Journal of Gynaecological Oncology. 1995;16(3):203-207.
Veneziano, M. ; Framarino dei Malatesta, M. ; Bandiera, A. F. ; Fiorelli, C. ; Galati, M. ; Paolucci, A. / Ondansetron-induced headache Our experience in gynecological cancer. In: European Journal of Gynaecological Oncology. 1995 ; Vol. 16, No. 3. pp. 203-207.
@article{1c156857642f4ea990ae629dbd30e87e,
title = "Ondansetron-induced headache Our experience in gynecological cancer",
abstract = "Chemotherapy-induced emesis is one of the major problems in the treatment of oncologic patients. Recently, a novel class of compounds, the selective 5HT3 receptor antagonists, has been introduced, achieving a dramatic improvement in the control of emesis. The absence of extrapyramidal side effects adds to their safety and good tolerability. The Authors herein analyse their experience on 269 cycles of chemotherapy in 47 patients treated for gynaecological and breast malignancies, with particular regard to adverse events such as headache. Their most frequent side-effects are headache and constipation, that are usually mild and self-limiting. Nevertheless, in some cases, severe, rebel headache has been reported, leading in our experience in 6.4{\%} of cases to discontinuation of the antiemetic regimen. A previous history of recurrent or severe headache or migraine is not correlated with the occurrence of ondansetron-induced headache, as severe headache occurred after ondansetron only in 28.4{\%} of the patients with positive anamnesis, and 70{\%} of the patients that experienced had never suffered from severe headache before. In those patients complaining of severe headache, the Authors suggest an antiemetic association, with a loading dose of ondansetron i.v., followed by metoclopramide i.m. orally for the following days.",
keywords = "Headache, Ondansetron, Side effects",
author = "M. Veneziano and {Framarino dei Malatesta}, M. and Bandiera, {A. F.} and C. Fiorelli and M. Galati and A. Paolucci",
year = "1995",
language = "English",
volume = "16",
pages = "203--207",
journal = "European Journal of Gynaecological Oncology",
issn = "0392-2936",
publisher = "S.O.G. CANADA Inc.",
number = "3",

}

TY - JOUR

T1 - Ondansetron-induced headache Our experience in gynecological cancer

AU - Veneziano, M.

AU - Framarino dei Malatesta, M.

AU - Bandiera, A. F.

AU - Fiorelli, C.

AU - Galati, M.

AU - Paolucci, A.

PY - 1995

Y1 - 1995

N2 - Chemotherapy-induced emesis is one of the major problems in the treatment of oncologic patients. Recently, a novel class of compounds, the selective 5HT3 receptor antagonists, has been introduced, achieving a dramatic improvement in the control of emesis. The absence of extrapyramidal side effects adds to their safety and good tolerability. The Authors herein analyse their experience on 269 cycles of chemotherapy in 47 patients treated for gynaecological and breast malignancies, with particular regard to adverse events such as headache. Their most frequent side-effects are headache and constipation, that are usually mild and self-limiting. Nevertheless, in some cases, severe, rebel headache has been reported, leading in our experience in 6.4% of cases to discontinuation of the antiemetic regimen. A previous history of recurrent or severe headache or migraine is not correlated with the occurrence of ondansetron-induced headache, as severe headache occurred after ondansetron only in 28.4% of the patients with positive anamnesis, and 70% of the patients that experienced had never suffered from severe headache before. In those patients complaining of severe headache, the Authors suggest an antiemetic association, with a loading dose of ondansetron i.v., followed by metoclopramide i.m. orally for the following days.

AB - Chemotherapy-induced emesis is one of the major problems in the treatment of oncologic patients. Recently, a novel class of compounds, the selective 5HT3 receptor antagonists, has been introduced, achieving a dramatic improvement in the control of emesis. The absence of extrapyramidal side effects adds to their safety and good tolerability. The Authors herein analyse their experience on 269 cycles of chemotherapy in 47 patients treated for gynaecological and breast malignancies, with particular regard to adverse events such as headache. Their most frequent side-effects are headache and constipation, that are usually mild and self-limiting. Nevertheless, in some cases, severe, rebel headache has been reported, leading in our experience in 6.4% of cases to discontinuation of the antiemetic regimen. A previous history of recurrent or severe headache or migraine is not correlated with the occurrence of ondansetron-induced headache, as severe headache occurred after ondansetron only in 28.4% of the patients with positive anamnesis, and 70% of the patients that experienced had never suffered from severe headache before. In those patients complaining of severe headache, the Authors suggest an antiemetic association, with a loading dose of ondansetron i.v., followed by metoclopramide i.m. orally for the following days.

KW - Headache

KW - Ondansetron

KW - Side effects

UR - http://www.scopus.com/inward/record.url?scp=0029007349&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029007349&partnerID=8YFLogxK

M3 - Article

VL - 16

SP - 203

EP - 207

JO - European Journal of Gynaecological Oncology

JF - European Journal of Gynaecological Oncology

SN - 0392-2936

IS - 3

ER -